[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112016011430A2 - agentes anticâncer e preparação dos mesmos. - Google Patents

agentes anticâncer e preparação dos mesmos.

Info

Publication number
BR112016011430A2
BR112016011430A2 BR112016011430A BR112016011430A BR112016011430A2 BR 112016011430 A2 BR112016011430 A2 BR 112016011430A2 BR 112016011430 A BR112016011430 A BR 112016011430A BR 112016011430 A BR112016011430 A BR 112016011430A BR 112016011430 A2 BR112016011430 A2 BR 112016011430A2
Authority
BR
Brazil
Prior art keywords
preparation
anticancer agents
anticancer
agents
Prior art date
Application number
BR112016011430A
Other languages
English (en)
Other versions
BR112016011430B1 (pt
Inventor
K Ghosh Arun
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of BR112016011430A2 publication Critical patent/BR112016011430A2/pt
Publication of BR112016011430B1 publication Critical patent/BR112016011430B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR112016011430-2A 2013-11-19 2014-11-19 Compostos, conjugado de anticorpo, composição farmacêutica os compreendendo e seus usos BR112016011430B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361906133P 2013-11-19 2013-11-19
US61/906,133 2013-11-19
PCT/US2014/066458 WO2015077370A1 (en) 2013-11-19 2014-11-19 Anti-cancer agents and preparation thereof

Publications (2)

Publication Number Publication Date
BR112016011430A2 true BR112016011430A2 (pt) 2017-09-12
BR112016011430B1 BR112016011430B1 (pt) 2022-09-13

Family

ID=53180106

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016011430-2A BR112016011430B1 (pt) 2013-11-19 2014-11-19 Compostos, conjugado de anticorpo, composição farmacêutica os compreendendo e seus usos

Country Status (20)

Country Link
US (1) US10000505B2 (pt)
EP (1) EP3071563B1 (pt)
JP (2) JP6937578B2 (pt)
KR (1) KR102428737B1 (pt)
CN (3) CN105829299A (pt)
AU (1) AU2014353087B2 (pt)
BR (1) BR112016011430B1 (pt)
CA (1) CA2931111C (pt)
CL (1) CL2016001209A1 (pt)
DK (1) DK3071563T3 (pt)
EA (1) EA035262B1 (pt)
ES (1) ES2943711T3 (pt)
FI (1) FI3071563T3 (pt)
IL (2) IL245637B (pt)
MX (1) MX2016006591A (pt)
MY (1) MY189459A (pt)
PE (1) PE20161240A1 (pt)
PH (1) PH12016500924A1 (pt)
PT (1) PT3071563T (pt)
WO (1) WO2015077370A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3071563B1 (en) 2013-11-19 2023-04-19 Purdue Research Foundation Anti-cancer agents and preparation thereof
WO2017214423A2 (en) * 2016-06-08 2017-12-14 William Marsh Rice University Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof
AU2017331260B2 (en) 2016-09-23 2024-11-07 Purdue Research Foundation Anti-cancer agents and preparation thereof
MX2020003089A (es) 2017-09-20 2020-10-15 Ph Pharma Co Ltd Analogos de tailanstatina.
CN109020876A (zh) * 2018-09-21 2018-12-18 大连理工大学 一种新型6-羟基-2h-二氢吡啶-3-酮的制备方法
CN115698018A (zh) * 2020-04-09 2023-02-03 百时美施贵宝公司 美亚霉素类似物和使用方法
CN113563361B (zh) * 2021-08-17 2022-05-20 浙江珲达生物科技有限公司 一种从伯克霍尔德菌发酵液提取fr901464的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
US7825267B2 (en) * 2006-09-08 2010-11-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of FR901464 and analogs with antitumor activity
AR070865A1 (es) 2008-03-18 2010-05-12 Genentech Inc Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso
AR080234A1 (es) 2010-02-25 2012-03-21 Marrone Bio Innovations Inc Cepa bacteriana aislada del genero burkholderia y metabolitos pesticidas del mismo
KR20160054627A (ko) * 2011-08-27 2016-05-16 마론 바이오 이노베이션스, 인코포레이티드 부르크홀데리아 속의 단리된 박테리아 균주 및 그로부터의 살충 대사물-제제 및 용도
WO2014068443A1 (en) * 2012-11-05 2014-05-08 Pfizer Inc. Spliceostatin analogs
EP3071563B1 (en) 2013-11-19 2023-04-19 Purdue Research Foundation Anti-cancer agents and preparation thereof

Also Published As

Publication number Publication date
DK3071563T3 (da) 2023-05-08
CN113461705A (zh) 2021-10-01
PE20161240A1 (es) 2016-11-27
CN105829299A (zh) 2016-08-03
KR102428737B1 (ko) 2022-08-02
IL245637B (en) 2021-05-31
NZ759166A (en) 2022-03-25
CA2931111A1 (en) 2015-05-28
EP3071563A1 (en) 2016-09-28
MX2016006591A (es) 2017-05-30
FI3071563T3 (fi) 2023-05-29
KR20160086411A (ko) 2016-07-19
MY189459A (en) 2022-02-14
IL282430A (en) 2021-06-30
JP2017503753A (ja) 2017-02-02
CN113773333A (zh) 2021-12-10
WO2015077370A1 (en) 2015-05-28
EA201691010A1 (ru) 2016-11-30
EP3071563B1 (en) 2023-04-19
EA035262B1 (ru) 2020-05-21
ES2943711T3 (es) 2023-06-15
US20160297831A1 (en) 2016-10-13
JP6929903B2 (ja) 2021-09-01
IL245637A0 (en) 2016-06-30
AU2014353087B2 (en) 2018-07-19
BR112016011430B1 (pt) 2022-09-13
US10000505B2 (en) 2018-06-19
EP3071563A4 (en) 2017-09-06
PH12016500924A1 (en) 2016-07-18
JP2019189644A (ja) 2019-10-31
NZ721152A (en) 2022-03-25
AU2014353087A1 (en) 2016-06-30
CA2931111C (en) 2022-03-15
CL2016001209A1 (es) 2017-06-02
PT3071563T (pt) 2023-05-09
JP6937578B2 (ja) 2021-09-22

Similar Documents

Publication Publication Date Title
FR21C1059I2 (fr) Compositions pharmaceutiques
CL2016001241A1 (es) Nuevos compuestos pesticidas y usos
CL2015001924A1 (es) Anticuerpos anti-pdgfr-beta y usos relacionados.
FR3006466B3 (fr) .
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
UA29910S (uk) Блендер
BR112015002790A2 (pt) anticorpos asgpr e usos dos mesmos.
BR112016016289A2 (pt) heteroaris e usos dos mesmos
BR112015001459A2 (pt) anticorpos anti-kit e usos dos mesmos.
BR302014001376S1 (pt) Configuração aplicada em bolsa.
BR302014000594S1 (pt) Configuração aplicada em cápsula
BR112016011430A2 (pt) agentes anticâncer e preparação dos mesmos.
FR3007989B1 (fr) Autoinjecteur.
FR3014017B1 (fr) Structure de securite
FR3013601B1 (fr) Autoinjecteur.
DK3068505T3 (da) Spillesystem og -fremgangsmåde
CL2014002083A1 (es) Tionocarbamatos y procesos de preparacion.
FR3001302B1 (fr) .
DK3003401T3 (da) Farmaceutisk præparat
BR112015023621A2 (pt) derivados de menopenem e usos dos mesmos
DK2983747T3 (da) Lægemiddelindgivelsesindretning
DK2972363T3 (da) Immunpotenserende nanobærerlægemiddel
FR3001303B1 (fr) .
FR3012342B1 (fr) Puzzle
TH1501001333B (th) สารผสมกำจัดวัชพืชซึ่งประกอบรวมด้วยอะมิโนไพราลิด และไตรโคลไพร์

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/11/2014, OBSERVADAS AS CONDICOES LEGAIS